Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they ...

Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca.

Direct multi-KRAS inhibitors, QTX3034 and QTX3544, exhibit potent activity against established and novel resistance mechanisms to ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...

RAS genes are the second most frequently mutated genes in cancer, and mutant RAS proteins are key drivers of some of the deadliest cancers, including nearly all pancreatic cancers, half of colorectal ...

A blue protein ribbon structure labeled PI3Kα has a space-filling molecule bound to it, which interacts (clashes) with a second protein ribbon molecule labeled KRas. This model shows how BBO-10203 ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...

Proteins that are commonly mutated and overexpressed in cancers are called oncoproteins and are typical targets for cancer therapies. Cancer treatment faces significant challenges due to the presence ...

Testing older potential organ donors for dangerous "zombie" cells could help to increase the number of hearts available for transplant, according to research presented at the British Cardiovascular ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their ...